PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 82926

Title: Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03908850

Position: Peer Reviewer

Academic degree: BSc, MD

Professional title: Doctor, Research Scientist, Staff Physician, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2022-12-30

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-01-06 17:02

Reviewer performed review: 2023-01-06 17:20

Review time: 1 Hour

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty

Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation
Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thank you for the possibility to review the manuscript titled: "Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and literature review." This is a very rare case of a patient with metastasis to the scalp. There are only incidental reports of such patients in the literature. There are only a few minor recommendations: -"The operation went smoothly and the postoperative recovery of the patient was good", the phrase "went smoothly" is not a valid academic term. I would recommend using "went without complications" or "went without any particularities" -Please indicate which TI-RADS system was used in the manuscript (Chinese, American Korean or other). -I would recommend adding a small table about vandetanib, cabozantinib, sorafenib and lenvatinib in the discussion section, paying more attention to these drugs.   Please take into account the recommendations in the spirit of improving the quality of the submission.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 82926

Title: Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 01551432

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-12-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-01-06 11:57

Reviewer performed review: 2023-01-09 00:54

Review time: 2 Days and 12 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [Y] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear Authors, Thank you for submitting your manuscript entitled, "Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and literature review". The manuscript is well written, and the topic is interesting and timely. However, several major criticisms should be addressed as the followings.   1. The patient underwent surgery for primary lung cancer, but it is questionable whether the thyroid gland or the lungs were primary or not. It would be better to extract DNA from the tumor tissue and perform next-generation sequencing to check for mutations such as TERT promoter mutation, PET fusion, TP53, etc., citing the following article. If impossible, please cite at least the following article and add a sufficient description on this important subject in the "Discussion section". Qing Li, et al. Frontiers in Oncology 2021:11;569429   2. The description is lucks accuracy. I think the final diagnosis is incorrectly listed. Correctly, it should read "Scalp metastasis, skull metastasis, right upper lung metastasis (or primary right lung cancer?) Cervical lymph node metastasis? It appears to be "bilobed papillary carcinoma of the thyroid gland with Please correct. Further, are their any metastasis in the military column and cervical

lymph node? Please add the proper descriptions on these subjects. 3. there are no macroscopic photographs of the resected specimens of primary and metastatic lesions and micrographs of the pathology. Shouldn't this always be necessary in discussing whether the lung or thyroid is the primary site? Therefore, the final diagnosis is suspiciously unreliable. 4. Treatment: What exactly are "3 cycles of anlotinib therapy", "self-reported targeted drug therapy" and "iodine-131 therapy" given continuously after surgery in combination with anlotinib? Please describe the drugs, doses and regimens in detail. 5. Please search the literature such as Medline, etc., and list several case reports or case series similar or identical to your submitted case, and please create a new table summarizing their characteristics in terms of age, sex, histological type, treatment, clinical course, prognosis. Furthermore, please consider if there are any common characteristics among these case groups. Please review them and add the description to the "Discussion section. 6. Please add a new schematic figure and brief explanations in the "Discussion section" about the mechanism of action of TKI to show anti-tumor effect, so that the readers of WJCC can easily understand it. 7. Please add one new summarized table explaining the treatment and clinical course of this case for the WJCC readers to understand easily. 8. I think the "Discussion section" is rather poorly written. #1. Please add the author's own thoughts on the reasons and appropriateness of each treatment procedures selected during the course of this case. #2. Why don't you also add the experimental results showing that anlotinib is effective in PTC in the "Discussion section"? For example, the following review article is detailed and clear: X Ryan, et al. Endocrine-Related Cancer 2019;26:153-164

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Peer-reviewer	Peer-Review: [ ] Anonymous [Y] Onymous

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear Authors,   Thank you for resubmiting your manuscript. The manuscript is properly revised accordingly. I think it is OK as it stands.   Thank you.   Sincerely yours, Takuya Watanabe, MD,PhD. Watanabe Internal Medicine Aoyama Clinic Niigata,Japan